logo-loader
viewMedexus Pharmaceuticals Inc

Canaccord initiates coverage of Medexus Pharmaceuticals with Buy rating, C$6.50 price target

The Canadian equity research firm noted that Medexus has 18 products and 48 sales representatives and produces more than C$50 million in trailing revenue

abstract design
The company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases

Canaccord Genuity on Tuesday initiated coverage of Medexus Pharmaceuticals Inc (CVE:MDP) (OTCMKTS:PDDPF) with a Buy rating and a C$6.50 price target. 

Medexus’ stock trades around C$4.12 a share in Toronto.

The Canadian equity research firm noted that Medexus, which consolidated with Pediapharm Inc and Medac Pharma USA last year, has 18 products and 48 sales representatives and produces more than C$50 million in trailing revenue. 

READ: Medexus Pharmaceuticals receives boost for its Gliolan drug as Health Quality Ontario recommends public funding

“With 88% of current sales attributable to products in the growth or launch phase, we believe this is just the beginning of several years of double-digit growth,” analyst Tania Gonsalves wrote.

“Accounting for operating leverage off the partially fixed-cost sales infrastructure, we forecast EBITDA margins expanding from mid-single digits toward the industry average of 25-30% within five years.”

The Montreal-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases.

“Although (both drugs) already represent an estimated 70% of MDP's sales, both products are still early in their life cycles,” Gonsalves said.  

“We expect them to peak in F2024 and F2023 before falling off patent in July 2027 and June 2029, respectively. By F2023, they represent around 60% of our $125 million sales forecast.”

READ: Medexus Pharmaceuticals posts fiscal 1Q results showing healthy year-over-year rise in revenue

Gonsalves also noted that Medexus’s consolidaition with Pediapharm and Medac is “expected to yield healthy synergies.” Pediapharm had acquired both companies but kept the Medexus name.  

She also said “we believe MDP is now adequately funded ($27M of cash, $42M convertible debentures maturing October 2023) and fully staffed to execute its strategic vision.”

In other company news, Sylvain Chrétien will no longer serve as the company’s president of Canadian operations and will resign from the board. In addition. Benoît Hébert will be departing as the company’s vice president of business development & licensing.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Medexus Pharmaceuticals Inc

Price: 3.86 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $56.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Medexus Pharmaceuticals unveils jump in 1Q revenue,...

Medexus Pharmaceuticals Inc (CVE:KMDP) (OTCMKTS:PDDPF) CEO Ken d'Entremont stopped by Proactive New York to talk about the Canadian-based biopharma's fiscal first-quarter results, which showed a year-over-year jump in revenue jump to C$16.1 million, and positive EBITDA of C$0.5...

on 28/8/19

2 min read